
- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About Chinook Thera
Chinook Therapeutics, Inc., formerly Aduro Biotech, Inc., is a clinical-stage biotechnology company. The Company develops precision medicines for kidney diseases. The Company’s products focus on severe chronic kidney disorders. The Company assembled a portfolio of precision medicines product candidates designed to address severe chronic kidney diseases. Its development programs consist of atrasentan, BION-1301 and CHK-336. Atrasentan, a potent and selective endothelin receptor antagonist that the Company is developing for treatment of primary glomerular diseases, including IgAN. IgAN is a serious progressive autoimmune disease of the kidney. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase 1b trial for IgA nephropathy. CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other chronic kidney diseases, including polycystic kidney disease.
Stock Analysis
